ERBB3 and breast carcinoma: While chromatin immunoprecipitation and in vitro transcription assays would ultimately be required for final experimental proof, our results nonetheless suggest a novel model whereby JAM-A regulates the expression of HER3 in breast cancer cells (independently of HER2 expressional status) by first altering the expression of the known HER3 transcription factor FOXA1.